MedTrace Logo

Evaluate the Efficacy and Safety of DWJ211 in Patient With Moderate or Severe Submental Fat

NCT03946592 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 148

Last updated 2024-04-04

No results posted yet for this study

Summary

Evaluate the efficacy and safety of DWJ211 in patient with moderate or severe submental fat

Conditions

  • Submental Fat

Interventions

DRUG

Normal saline

Inject the Drug into submental fat via subcutaneous

DRUG

DWJ211

Inject the Drug into submental fat via subcutaneous

Sponsors & Collaborators

  • Daewoong Pharmaceutical Co. LTD.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-05-15
Primary Completion
2020-07-02
Completion
2020-07-02

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03946592 on ClinicalTrials.gov